Article

Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis

Interstitial Lung Disease Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, , London, UK.
Thorax (Impact Factor: 8.56). 01/2013; 68(5). DOI: 10.1136/thoraxjnl-2012-201786
Source: PubMed

ABSTRACT BACKGROUND: A polymorphism (rs35705950) 3 kb upstream of MUC5B, the gene encoding Mucin 5 subtype B, has been shown to be associated with familial and sporadic idiopathic pulmonary fibrosis (IPF). We set out to verify whether this variant is also a risk factor for fibrotic lung disease in other settings and to confirm the published findings in a UK Caucasian IPF population. METHODS: Caucasian UK healthy controls (n=416) and patients with IPF (n=110), sarcoidosis (n=180) and systemic sclerosis (SSc) (n=440) were genotyped to test for association. The SSc and sarcoidosis cohorts were subdivided according to the presence or absence of fibrotic lung disease. To assess correlation with disease progression, time to decline in forced vital capacity and/or lung carbon monoxide transfer factor was used in the IPF and SSc groups, while a persistent decline at 4 years since baseline was evaluated in patients with sarcoidosis. RESULTS: A significant association of the MUC5B promoter single nucleotide polymorphism with IPF (p=2.04×10(-17); OR 4.90, 95% CI 3.42 to 7.03) was confirmed in this UK population. The MUC5B variant was not a risk factor for lung fibrosis in patients with SSc or sarcoidosis and did not predict more rapidly progressive lung disease in any of the groups. Rather, a trend for a longer time to decline in forced vital capacity was observed in patients with IPF. CONCLUSIONS: We confirm the MUC5B variant association with IPF. We did not observe an association with lung fibrosis in the context of SSc or sarcoidosis, potentially highlighting fundamental differences in genetic susceptibility, although the limited subgroup numbers do not allow a definitive exclusion of an association.

0 Followers
 · 
102 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Polymorphisms in the MUC5B promoter, TOLLIP gene, and nine additional genetic loci have been associated with idiopathic pulmonary fibrosis (IPF) within non-Hispanic white populations. It is unknown whether these variants account for risk of IPF in other racial/ethnic populations. We conducted a candidate SNP association study in cohorts of Mexican and Korean IPF patients. Methods:We chose 12 SNPs from 11 loci that are associated with IPF among non-Hispanic whites and genotyped these SNPs in cohorts of Mexican (83 cases, 111 controls) and Korean (239 cases, 87 controls) subjects. Each SNP was tested for association with IPF, after adjusting for age and sex. Results:The MUC5B promoter SNP rs35705950 was associated with IPF in the Mexican (OR=7.36, p-value=1.1x10-4), but not the Korean (p-value=.99) cohort. The SNP in the IVD gene (chromosome15, rs2034650) was significantly associated with pulmonary fibrosis in both the Mexican (OR=0.40, p-value=0.01) and Korean (OR=0.13, p-value=8.1x10-4) cohorts. In the Korean cohort, there were no other variants associated with disease. In the Mexican cohort, SNPs on chromosomes 3, 4, and 11 were also associated with disease. Conclusions:The strongest identified genetic risk factor for IPF among the non-Hispanic white population, the MUC5B promoter polymorphism, is also a strong risk factor in a Mexican population, but is very rare in a Korean population. The majority of genetic variants that account for risk of IPF in groups other than non-Hispanic whites are unknown. Hispanic and Asian populations should be studied separately to identify genetic risk loci for IPF.
    Chest 10/2014; 147(2). DOI:10.1378/chest.14-0867 · 7.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:The current UIP/IPF CT classification system excludes probable UIP as a diagnostic category. We sought to determine the predictive effect of probable CT UIP on histology, and to determine the effect of the promoter polymorphism in the MUC5B gene (rs35705950) on histologic and CT UIP diagnosis. Methods:The cohort included 201 subjects with pulmonary fibrosis who had lung tissue samples obtained within one year of chest CT. UIP diagnosis on CT was categorized as inconsistent with, indeterminate, probable, or definite UIP by 2-3 pulmonary radiologists. Tissue slides were scored by two expert pulmonary pathologists. All subjects with available DNA (N=200) were genotyped for rs35705950. Results:The proportion of CT diagnoses were as follows: inconsistent with 69/201 (34.3%), indeterminate 72/201 (35.8%), probable 34/201 (16.9%), and definite 26/201 (12.9%) UIP. Subjects with probable CT UIP were more likely to have histologic probable/definite UIP than subjects with indeterminate CT UIP (82.4% [28/34] versus 54.2% [39/72]; p-value 0.01). CT and microscopic honeycombing were not associated with each other (p-value 0.76). The minor (T) allele of the MUC5B polymorphism was associated with concordant CT and histologic UIP diagnosis (p-value: 0.03). Conclusions:Probable CT UIP is associated with a higher rate of histologic UIP than indeterminate CT UIP suggesting that they are distinct groups and should not be combined into a single CT category as currently recommended by guidelines. CT and microscopic honeycombing may be dissimilar entities. The T allele at rs35705950 predicts a UIP diagnosis by both chest CT and histology.
    Chest 10/2014; DOI:10.1378/chest.14-0976 · 7.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The period covered by this update can be considered as the most exciting period in idiopathic pulmonary fibrosis (IPF) research. It started with the identification of genetic variants that are associated with IPF in the majority of patients and continued with discovery of molecular and genetic biomarkers that predict distinct clinical presentations of patients with IPF and potential new biological mechanisms. More importantly, the period ends with the publication of two groundbreaking studies that confirmed that two drugs, pirfenidone and nintedanib, slowed disease progression, leading to a historic approval by the FDA. In this update, we describe these key advances, their scientific and significant clinical implications, and future directions.
    American Journal of Respiratory and Critical Care Medicine 02/2015; 191(3):270-274. DOI:10.1164/rccm.201405-0856UP · 11.99 Impact Factor